Progenetica Diagnóstico Molecular

What Progenetica Diagnóstico Molecular does

Progenetica Diagnóstico Molecular is a Brazilian molecular oncology diagnostics laboratory operating as a wholly-owned subsidiary of Grupo Hermes Pardini, a diversified Brazilian healthcare conglomerate. The company specializes in hereditary cancer panels with Copy Number Variation (CNV) analysis and was one of the first institutions in Brazil to implement high-complexity molecular tests. It serves oncologists, geneticists, and oncology healthcare providers, as well as patients with suspected hereditary cancer syndromes, operating under a B2B2C model in which physicians order tests that are processed in Progenética's laboratory and results returned to the prescribing clinician.

The company's core technology is high-complexity molecular diagnostics, with its flagship offering being hereditary cancer panel testing that includes CNV detection — a methodology that identifies structural genomic variations relevant to cancer predisposition. Progenética is part of a coordinated Grupo Pardini sub-brand ecosystem that includes DLE (human genetics, rare diseases, genomics, and neonatal screening), Diagnóstika (anatomical pathology, molecular pathology, immunohistochemistry), and Biocod (genetic counseling). This structure gives the entity access to a network spanning 8000+ diagnostic tests, 600+ affiliated physicians, and over 200M in group-level technology investment, with national coverage across Brazil.

Progenética generates revenue through fee-for-service molecular diagnostic testing as a reference laboratory within the Pardini network. Pricing is not publicly disclosed and is handled through direct contact channels (phone line 4020-2888 and the email [email protected]). The company maintains a small core team of 9 employees but draws on a broader scientific advisory bench of approximately 15 multidisciplinary specialists covering medicine, biology, biochemistry, bioinformatics, pharmacy, and chemistry. Marketing and patient/physician engagement are conducted through a dedicated personalized medicine portal and Grupo Pardini's active social media presence across Facebook, Instagram, LinkedIn, Twitter, and YouTube.

Name

Progenetica Diagnóstico Molecular

Legal name

Progenetica Diagnóstico Molecular

Website

https://progenetica.com.br

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Progenetica Diagnóstico Molecular is a Brazilian molecular oncology laboratory and subsidiary of Grupo Hermes Pardini that provides hereditary cancer panel testing with Copy Number Variation (CNV) analysis to oncologists, geneticists, and patients across Brazil.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Population Genomics & Preventive Precision Health Programs (HLAAANAL), Proteomics & Biomarker Analytical Testing (HLAGADAG), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Molecular diagnostics
• Hereditary cancer testing
• Oncogenetics
• Personalized medicine
• Molecular oncology

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Testing Services: Progenética generates revenue through fee-for-service molecular diagnostic testing. As a reference laboratory in molecular oncology, it processes tests ordered by healthcare providers across Brazil, with samples analyzed and results returned to prescribing physicians.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Progenética is a reference laboratory in molecular oncology within Grupo Pardini, specializing in hereditary cancer panels with Copy Number Variation (CNV) analysis. The company was one of the first institutions in Brazil to implement high-complexity molecular tests, serving oncologists, geneticists, and healthcare providers across Brazil. It offers diagnostic testing services as part of Brazil's largest personalized medicine portfolio, encompassing nine medical specialties.

Product overview

Progenética is a molecular oncology company within the Grupo Pardini, offering hereditary cancer panels with CNV (Copy Number Variation) analysis. It is part of a broader portfolio of personalized medicine services that includes DLE (Human Genetics, Rare Diseases, and Genomics), Diagnóstika (Anatomical Pathology, Molecular Pathology, and Immunohistochemistry), and Biocod (Genetic Counseling). The company provides specialized diagnostic services across multiple medical specialties including cardiology, endocrinology, pharmacogenetics, medical genetics, hematology, neurology, oncology, reproduction, and neonatal screening, collectively representing the largest personalized medicine portfolio in Brazil.

Differentiator

Problem solved

Functional benefit

Products and services

• Painéis de Câncer Hereditário com Análise de CNVs (Hereditary Cancer Panels with CNV Analysis) Hereditary cancer panels with Copy Number Variation (CNV) analysis for identifying genetic predisposition to cancer. Offered to oncologists, geneticists, and healthcare providers across Brazil through Progenética as a reference laboratory.
• Progenética - Oncologia Laboratorial (Molecular Oncology Laboratory Services) Molecular oncology laboratory services including oncogenetics testing for healthcare providers. Pioneer in Oncogenetics Laboratorial in Brazil, serving as the molecular oncology reference lab within the Grupo Pardini network.

Quantifiable outcome

• One of the first institutions in Brazil to implement high-complexity molecular exams

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Grupo PardinicoreStrategic or Co-development PartnerProgenética is an integral company within Grupo Pardini, a major Brazilian laboratory group. The partnership provides Progenética with access to a comprehensive network including DLE (Genetics, Rare Diseases, Genomics, Neonatal Screening), Diagnóstika (Anatomical Pathology, Molecular Pathology, Immunohistochemistry), and Biocod (Genetic Counseling). This integration enables cross-referrals, shared technology infrastructure, and a combined portfolio of 8000+ diagnostic tests.

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Quest Diagnostics: Large global reference laboratory offering hereditary cancer panels and molecular oncology testing; relevant peer for Progenética in terms of test menu breadth, physician service model, and operational scale.
• Natera: Molecular diagnostics company with oncology and hereditary cancer testing products; comparable in molecular oncology positioning and CNV/SNV-based panel approach.
• Invitae: US-based genetic testing company offering hereditary cancer panels with CNV detection at scale; directly comparable in test menu and clinical use case to Progenética's core hereditary cancer offering.
• Fleury Medicina e Saúde: Major Brazilian diagnostic medicine company offering a broad menu of clinical and molecular tests including oncology genetics; competes with Progenética at the high-complexity end while serving many more specialties.
• Caris Life Sciences: US molecular oncology company specializing in comprehensive tumor profiling and hereditary cancer testing, providing a peer benchmark for Progenética's molecular oncology and CNV-based testing strategy.
• Myriad Genetics: Established US-based molecular diagnostics company specializing in hereditary cancer testing (BRACAnalysis, myRisk) — a global benchmark against which Progenética's hereditary cancer panels compete on clinical accuracy and panel comprehensiveness.
• SOPHiA Genetics: Global genomics and molecular diagnostics platform powering hereditary cancer and somatic oncology testing for reference labs; competes with Progenética's assay-level offerings via partnerships with Brazilian and international labs.
• Exact Sciences (Genomic Health): US diagnostics company offering oncology-focused molecular tests (e.g., Oncotype DX); comparable to Progenética as an oncology molecular diagnostics specialist with established physician channel.

Direct peers

• Mendelics Análise Genômica: Brazilian genomics and molecular diagnostics laboratory offering hereditary cancer panels and genetic testing nationwide, directly competing with Progenética in the domestic molecular oncology market.

Regional players

• DB Molecular Diagnostics (Diagnósticos do Brasil): Brazilian clinical laboratory network offering molecular and specialty diagnostics including oncology, comparable to Progenética as a domestic reference lab competing in the same Brazilian market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/hermespardini
• YouTubeyoutube.com/channel/UC4xb0ywnPNE1vOHCJF3aEmg
• Facebookfacebook.com/hermespardini
• LinkedInlinkedin.com/company/progenetica-diagn-stico-molecular
• Instagraminstagram.com/hermes.pardini/?hl=pt-br

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Progenetica Diagnóstico Molecular